Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Chemotherapeutic drug-photosensitizer co-assembled nanoparticles and construction thereof

A co-assembly and nanoparticle technology, which is applied in drug combinations, antineoplastic drugs, pharmaceutical formulations, etc., can solve the problems of easy crystallization or leakage of drugs, poor stability, toxic and side effects, etc., and achieve easy surface modification, small particle size, and easy Amplify the effect of production

Active Publication Date: 2019-05-07
SHENYANG PHARMA UNIVERSITY
View PDF0 Cites 15 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] With the development of nanotechnology, based on the existing formulation strategies, traditional nanocarriers can realize the co-encapsulation and delivery of chemotherapeutic drugs and photosensitizers, but there are problems such as low drug loading, poor stability, easy crystallization or leakage of drugs, and excipients. Toxic side effects and other issues

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Chemotherapeutic drug-photosensitizer co-assembled nanoparticles and construction thereof
  • Chemotherapeutic drug-photosensitizer co-assembled nanoparticles and construction thereof
  • Chemotherapeutic drug-photosensitizer co-assembled nanoparticles and construction thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0034] Example 1: Preparation of non-PEGylated mitoxantrone-pyropheophytin a co-assembled nanoparticles

[0035] A certain amount of mitoxantrone (MTX) and pyropheophytin a (PPa) were dissolved in a mixed solvent (methanol / tetrahydrofuran=50 / 50, v / v) to prepare 10mM MTX stock solution and 10mM PPa stock solution .

[0036] When the molar ratio of chemotherapeutic drug to photosensitizer was 6:1, the mixed solution (900 μL MTX solution and 150 μL PPa solution) was added dropwise to 3 mL deionized water at a stirring speed of 900 rpm. The organic solvent was removed by rotary evaporation under the condition of 25° C., and a precipitate was precipitated.

[0037] When the molar ratio of chemotherapeutic drug to photosensitizer was 3:1, the mixed solution (450 μL MTX solution and 150 μL PPa solution) was added dropwise to 3 mL deionized water at a stirring speed of 900 rpm. The organic solvent was removed by rotary evaporation under the condition of 25° C. to obtain the co-assem...

Embodiment 2

[0044] Example 2: Preparation of PEG-modified Mitoxantrone-pyropheophytin a co-assembled nanoparticles

[0045] A certain amount of mitoxantrone (MTX), pyropheophytin a (PPa), PEG modifier DSPE-PEG 2000 (5wt%PPa)) was dissolved in a mixed solvent (methanol / tetrahydrofuran=50 / 50, v / v) to prepare 10mM MTX stock solution, 10mM PPa stock solution and 1.0mg / mL DSPE-PEG 2000 stock solution. When the molar ratio of chemotherapeutics and photosensitizer is 1:3, the mixed solution (50 μL MTX solution, 150 μL PPa solution and 33.3 μL DSPE-PEG 2000 solution) was added dropwise to 3 mL of deionized water. The organic solvent was removed by rotary evaporation under the condition of 25° C., and the PEG-modified mitoxantrone-pyropheophytin a co-assembled nanoparticles were obtained. The drug loadings of MTX and PPa were 43.3% and 53.6%, respectively, achieving efficient co-loading of chemotherapeutic drugs and photosensitizers. The particle size of PEG-modified mitoxantrone and pyropheop...

Embodiment 3

[0046] Example 3: FBS stability test of PEG-modified mitoxantrone-pyropheophytin a co-assembled nanoparticles

[0047] The PEG-modified mitoxantrone-pyropheophytin a co-assembled nanoparticles prepared in Example 2 were incubated at 37°C in PBS of pH 7.4 containing 10% FBS for 12h, and at predetermined time points (0, 2, 4, 6, 8, 10, 12h) The particle size change was measured by dynamic light scattering method. The result is as image 3 As shown, the PEG-modified mitoxantrone-pyropheophytin a co-assembled nanoparticles did not change significantly in particle size within 12 hours, showing good FBS stability.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
particle diameteraaaaaaaaaa
Login to View More

Abstract

The invention belongs to the field of new auxiliary materials and new dosage forms of medicine preparations and relates to a chemotherapeutic drug-photosensitizer co-assembled nanoparticles and construction thereof. A chemotherapeutic drug is an anthracycline chemotherapeutic drug selected from mitoxantrone, doxorubicin or epirubicin; a photosensitizer is a porphyrin photosensitizer selected fromchlorine e6, hematoporphyrin monomethyl ether or a chlorophyll derivative, wherein the molar ratio of the chemotherapeutic drug to the photosensitizer is 3:1-1:3. A certain quantity of the chemotherapeutic drug and the photosensitizer or a mixture of the chemotherapeutic drug, the photosensitizer and PEG is dissolved in a proper quantity of organic solvent, and the solution is slowly dropwise added to water while stirring to form uniform nanoparticles spontaneously. The preparation process is simple, enlarged production is easy, particle size is small and uniform, and the nanoparticles can beenriched at tumor parts through a reinforced permeation retention effect; the nanoparticles have ultrahigh drug loading capacity and can reduce related toxicity of auxiliary materials; and surface modification is easy, and the circulation time of the nanoparticles in blood can be prolonged by PEG modification.

Description

technical field [0001] The invention belongs to the field of new excipients and new dosage forms of pharmaceutical preparations, and relates to the construction of chemotherapeutic drug-photosensitizer co-assembled nanoparticles and the construction thereof, in particular to the construction of a mitoxantrone-pyropheophytin a co-assembled nanoparticle and its application in drug delivery applications in the system. Background technique [0002] Cancer is a major disease that threatens human life and health. Chemotherapy is one of the effective strategies for cancer treatment, but most chemotherapeutic drugs have disadvantages such as low solubility, narrow therapeutic window, and certain toxic and side effects. With the continuous development of nanoscience in the field of medicine, in cancer treatment, nanomedicine such as Doxil (PEGylated doxorubicin liposome), Abraxane (paclitaxel albumin nanosuspension), Lipusu (paclitaxel liposome) And so on have been successfully lis...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/14A61K41/00A61K31/704A61K31/136A61P35/00
Inventor 孙进何仲贵王昭蒙孙孟驰
Owner SHENYANG PHARMA UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com